The Streblow Lab’s primary research focus includes, development of new models of viral infection,  characterization of viral pathogenesis mechanisms, understanding immune response to viral infection and investigating preventative measures that may inhibit diseases caused by new and emerging viruses.

Sars-Cov2

In March of 2020, the Streblow lab along with the Dept. of Pathology, was instrumental in establishing a clinical diagnostic laboratory at OHSU for the inhouse detection of COVID-19.  Our interest and research involving Covid-19 has now moved into NHP models to increase our understanding of viral infection pathology. 

Human Cytomegalovirus – Solid organ transplant rejection

Dr. Streblow’s interest in HCMV and its effect on transplant organ rejection has led his lab to develop a number of in vitro and in vivo models to determine the mechanisms of HCMV-accelerated solid organ and bone marrow graft rejection. We have characterized viral chemokine and chemokine receptor signaling and function with the aim of elucidating their roles in viral pathogenesis and transplant rejection. In addition, we have helped develop CMV vaccine vectors in mouse and rhesus-CMVs. We have developed reagents for the identification and quantification of virus and disease assessments as well as characterized both innate and adaptive (T and B cell) responses.

Emerging viruses

The Streblow lab is very interested in emerging viruses and has generated both mouse and NHP Zika virus, chikungunya virus (CHIKV) and Mayaro virus (MAYV) infection models. We have used these models to characterize alphavirus infection and define viral immune responses. These models are also used to evaluate small molecule therapeutics developed through our participation in the AD³C (U19 grant). The Streblow lab has also made a number of seminal discoveries by testing novel vaccines and therapeutic antibodies in these models.